Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends—an update. Cancer Epidemiol Biomarkers Prev. 2016;25(1):16–27. https://doi.org/10.1158/1055-9965.EPI-15-0578.

Article  PubMed  Google Scholar 

Feretis M, Solodkyy A. Yttrium-90 radioembolization for unresectable hepatic metastases of breast cancer: a systematic review. World J Gastrointest Oncol. 2020;12(2):228–36. https://doi.org/10.4251/wjgo.v12.i2.228.

Article  PubMed  PubMed Central  Google Scholar 

Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. https://doi.org/10.3322/caac.21654.

Article  PubMed  Google Scholar 

Hess KR, Varadhachary GR, Taylor SH, et al. Metastatic patterns in adenocarcinoma. Cancer. 2006;106(7):1624–33. https://doi.org/10.1002/cncr.21778.

Article  PubMed  Google Scholar 

Ma R, Feng Y, Lin S, et al. Mechanisms involved in breast cancer liver metastasis. J Transl Med. 2015;13:64. https://doi.org/10.1186/s12967-015-0425-0.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Adam R. Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases. Ann Oncol Off J Eur Soc Med Oncol. 2003;14 Suppl 2:ii13–6. https://doi.org/10.1093/annonc/mdg731

Saxena A, Kapoor J, Meteling B, Morris DL, Bester L. Yttrium-90 radioembolization for unresectable, chemoresistant breast cancer liver metastases: a large single-center experience of 40 patients. Ann Surg Oncol. 2014;21(4):1296–303. https://doi.org/10.1245/s10434-013-3436-1.

Article  PubMed  Google Scholar 

Terata K, Imai K, Wakita A, Sato Y, Motoyama S, Minamiya Y. Surgical therapy for breast cancer liver metastases. Transl Cancer Res. 2020;9(8):5053–62. https://doi.org/10.21037/tcr-20-1598.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Millen JCA, Hofmann A, Mesquita-Neto JW, Rose J, Macedo FI. Evolving role of liver resection in selected patients with metastatic breast cancer. J Surg Res. 2021;259:363–71. https://doi.org/10.1016/j.jss.2020.09.022.

Article  PubMed  Google Scholar 

Gordon AC, Gradishar WJ, Kaklamani VG, et al. Yttrium-90 radioembolization stops progression of targeted breast cancer liver metastases after failed chemotherapy. J Vasc Interv Radiol. 2014;25(10):1523-1532.e2. https://doi.org/10.1016/j.jvir.2014.07.007.

Article  PubMed  PubMed Central  Google Scholar 

Barakat E, Bibok A, Rishi A, et al. Transarterial Yttrium-90 glass microsphere radioembolization of chemotherapy-refractory breast cancer liver metastases: results of a single institution retrospective study. Adv Radiat Oncol. 2022;7(1): 100838. https://doi.org/10.1016/j.adro.2021.100838.

Article  PubMed  Google Scholar 

Padia SA. Y90 clinical data update: cholangiocarcinoma, neuroendocrine tumor, melanoma, and breast cancer metastatic disease. Tech Vasc Interv Radiol. 2019;22(2):81–6. https://doi.org/10.1053/j.tvir.2019.02.008.

Article  PubMed  Google Scholar 

Pieper CC, Meyer C, Wilhelm KE, et al. Yttrium-90 radioembolization of advanced, unresectable breast cancer liver metastases—a single-center experience. J Vasc Interv Radiol. 2016;27(9):1305–15. https://doi.org/10.1016/j.jvir.2016.05.028.

Article  PubMed  Google Scholar 

Bester L, Meteling B, Pocock N, et al. Radioembolization versus standard care of hepatic metastases: comparative retrospective cohort study of survival outcomes and adverse events in salvage patients. J Vasc Interv Radiol. 2012;23(1):96–105. https://doi.org/10.1016/j.jvir.2011.09.028.

Article  PubMed  Google Scholar 

Davisson NA, Bercu ZL, Friend SC, et al. Predictors of survival after Yttrium-90 radioembolization of chemotherapy-refractory hepatic metastases from breast cancer. J Vasc Interv Radiol. 2020;31(6):925–33. https://doi.org/10.1016/j.jvir.2019.12.013.

Article  PubMed  Google Scholar 

Schatka I, Tschernig M, Rogasch JMM, et al. Selective internal radiation therapy in breast cancer liver metastases: outcome assessment applying a prognostic score. Cancers (Basel). 2021;13(15):3777. https://doi.org/10.3390/cancers13153777.

CAS  Article  Google Scholar 

Cianni R, Pelle G, Notarianni E, et al. Radioembolisation with 90Y-labelled resin microspheres in the treatment of liver metastasis from breast cancer. Eur Radiol. 2013;23(1):182–9. https://doi.org/10.1007/s00330-012-2556-5.

CAS  Article  PubMed  Google Scholar 

Garin E, Rolland Y, Laffont S, Edeline J. Clinical impact of (99m)Tc-MAA SPECT/CT-based dosimetry in the radioembolization of liver malignancies with (90)Y-loaded microspheres. Eur J Nucl Med Mol Imaging. 2016;43(3):559–75. https://doi.org/10.1007/s00259-015-3157-8.

CAS  Article  PubMed  Google Scholar 

Salem R, Lewandowski RJ, Gates VL, et al. Research reporting standards for radioembolization of hepatic malignancies. J Vasc Interv Radiol. 2011;22(3):265–78. https://doi.org/10.1016/j.jvir.2010.10.029.

Article  PubMed  PubMed Central  Google Scholar 

Hermann A-L, Dieudonné A, Maxime R, et al. Role of 99mTc-macroaggregated albumin SPECT/CT based dosimetry in predicting survival and tumor response of patients with locally advanced and inoperable hepatocellular carcinoma (HCC) treated by selective intra-arterial radiation therapy (SIRT) with yttr. J Hepatol. 2018;68:S13. https://doi.org/10.1016/S0168-8278(18)30243-5.

Article  Google Scholar 

Kokabi N, Galt JR, Xing M, et al. A simple method for estimating dose delivered to hepatocellular carcinoma after Yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study. J Vasc Interv Radiol. 2014;25(2):277–87. https://doi.org/10.1016/j.jvir.2013.11.007.

Article  PubMed  Google Scholar 

Schwartz LH, Litière S, de Vries E, et al. RECIST 1.1—update and clarification: from the RECIST committee. Eur J Cancer. 2016;62:132–7. https://doi.org/10.1016/j.ejca.2016.03.081.

Article  PubMed  PubMed Central  Google Scholar 

Jh O, Lodge MA, Wahl RL. Practical PERCIST: a simplified guide to PET response criteria in solid tumors 1.0. Radiology. 2016;280(2):576–84. https://doi.org/10.1148/radiol.2016142043.

Article  Google Scholar 

Stuart JE, Tan B, Myerson RJ, et al. Salvage radioembolization of liver-dominant metastases with a resin-based microsphere: initial outcomes. J Vasc Interv Radiol. 2008;19(10):1427–33. https://doi.org/10.1016/j.jvir.2008.07.009.

Article  PubMed  Google Scholar 

Porkka K, Blomqvist C, Rissanen P, Elomaa I, Pyrhönen S. Salvage therapies in women who fail to respond to first-line treatment with fluorouracil, epirubicin, and cyclophosphamide for advanced breast cancer. J Clin Oncol. 1994;12(8):1639–47. https://doi.org/10.1200/JCO.1994.12.8.1639.

CAS  Article  PubMed  Google Scholar 

Zinser JW, Hortobagyi GN, Buzdar AU, Smith TL, Fraschini G. Clinical course of breast cancer patients with liver metastases. J Clin Oncol. 1987;5(5):773–82. https://doi.org/10.1200/JCO.1987.5.5.773.

CAS  Article  PubMed  Google Scholar 

Fendler WP, Lechner H, Todica A, et al. Safety, efficacy, and prognostic factors after radioembolization of hepatic metastases from breast cancer: a large single-center experience in 81 patients. J Nucl Med. 2016;57(4):517–23. https://doi.org/10.2967/jnumed.115.165050.

CAS  Article  PubMed  Google Scholar 

Gordon AC, Salem R, Lewandowski RJ. Yttrium-90 radioembolization for breast cancer liver metastases. J Vasc Interv Radiol. 2016;27(9):1316–9. https://doi.org/10.1016/j.jvir.2016.06.016.

Article  PubMed  Google Scholar 

Mackey JR, Venner PM. Malignant ascites: demographics, therapeutic efficacy and predictors of survival. Can J Oncol. 1996;6(2):474–480. http://www.ncbi.nlm.nih.gov/pubmed/12056099

Villalobos A, Soliman MM, Majdalany BS, et al. Yttrium-90 radioembolization dosimetry: what trainees need to know. Semin Interv Radiol. 2020;37(5):543–54. https://doi.org/10.1055/s-0040-1720954.

Article  Google Scholar 

Ho S, Lau WY, Leung TW, et al. Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumours. Eur J Nucl Med. 1996;23(8):947–52. https://doi.org/10.1007/BF01084369.

CAS  Article  PubMed  Google Scholar 

Levillain H, Bagni O, Deroose CM, et al. International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres. Eur J Nucl Med Mol Imaging. 2021;48(5):1570–84. https://doi.org/10.1007/s00259-020-05163-5.

Article  PubMed  PubMed Central  Google Scholar 

Cheng B, Sethi I, Davisson N, et al. Yttrium-90 dosimetry and implications on tumour response and survival after radioembolisation of chemo-refractory hepatic metastases from breast cancer. Nucl Med Commun. 2021;42(4):402–9. https://doi.org/10.1097/MNM.0000000000001345.

CAS  Article  PubMed  Google Scholar 

Ridouani F, Soliman MM, England RW, et al. Relationship of radiation dose to efficacy of radioembolization of liver metastasis from breast cancer. Eur J Radiol. 2021;136: 109539. https://doi.org/10.1016/j.ejrad.2021.109539.

Article  PubMed  PubMed Central  Google Scholar